chartexchange

Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026

JCN Newswire | Oct 16, 2026 11:31 AM EDT

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2026, taking place in Madrid from October 23 to 27. Together, the presentations reflect Eisai's ongoing commitment to generating evidence that can help inform treatment decisions for patients facing difficult-to-treat cancers.

Read original article